PL3897646T3 - Macytentan w leczeniu tętniczego nadciśnienia płucnego - Google Patents

Macytentan w leczeniu tętniczego nadciśnienia płucnego

Info

Publication number
PL3897646T3
PL3897646T3 PL19832954.2T PL19832954T PL3897646T3 PL 3897646 T3 PL3897646 T3 PL 3897646T3 PL 19832954 T PL19832954 T PL 19832954T PL 3897646 T3 PL3897646 T3 PL 3897646T3
Authority
PL
Poland
Prior art keywords
macitentan
treatment
arterial hypertension
pulmonary arterial
pulmonary
Prior art date
Application number
PL19832954.2T
Other languages
English (en)
Inventor
Dénes CSONKA
Wassim Fares
Hans HOOGKAMER
Koen TORFS
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=69147670&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3897646(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of PL3897646T3 publication Critical patent/PL3897646T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
PL19832954.2T 2018-12-21 2019-12-20 Macytentan w leczeniu tętniczego nadciśnienia płucnego PL3897646T3 (pl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP2018086724 2018-12-21
EP2019051830 2019-01-25
EP2019060151 2019-04-18
EP2019066494 2019-06-21
EP2019067186 2019-06-27
PCT/EP2019/086754 WO2020128017A1 (en) 2018-12-21 2019-12-20 Pharmaceutical composition for the treatment of pulmonary arterial hypertension

Publications (1)

Publication Number Publication Date
PL3897646T3 true PL3897646T3 (pl) 2024-07-22

Family

ID=69147670

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19832954.2T PL3897646T3 (pl) 2018-12-21 2019-12-20 Macytentan w leczeniu tętniczego nadciśnienia płucnego

Country Status (30)

Country Link
US (3) US11234980B2 (pl)
EP (1) EP3897646B1 (pl)
JP (2) JP7871054B2 (pl)
KR (1) KR20210109558A (pl)
CN (1) CN113194953A (pl)
AU (1) AU2019410727B2 (pl)
BR (1) BR112021011999A2 (pl)
CA (1) CA3123990A1 (pl)
CL (1) CL2021001636A1 (pl)
CO (1) CO2021007186A2 (pl)
DK (1) DK3897646T3 (pl)
ES (1) ES2983314T3 (pl)
FI (1) FI3897646T3 (pl)
HR (1) HRP20240875T1 (pl)
HU (1) HUE067126T2 (pl)
IL (1) IL284136A (pl)
JO (1) JOP20210153B1 (pl)
LT (1) LT3897646T (pl)
MA (1) MA54522B1 (pl)
MX (1) MX2021007455A (pl)
PH (1) PH12021551371A1 (pl)
PL (1) PL3897646T3 (pl)
PT (1) PT3897646T (pl)
RS (1) RS65689B1 (pl)
SG (1) SG11202105098VA (pl)
SI (1) SI3897646T1 (pl)
SM (1) SMT202400274T1 (pl)
TW (1) TWI841649B (pl)
WO (1) WO2020128017A1 (pl)
ZA (1) ZA202105111B (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA126122C2 (uk) 2017-02-27 2022-08-17 Ідорсія Фармасьютікалз Лтд Комбінації похідної 4-піримідинсульфаміду з активними інгредієнтами для лікування захворювань, пов'язаних з ендотеліном
WO2020074957A1 (en) * 2018-10-12 2020-04-16 Sanotize Research And Development Corp. Gas-evolving compositions and container and delivery systems
EP3897646B1 (en) 2018-12-21 2024-05-22 Actelion Pharmaceuticals Ltd Macitentan for the treatment of pulmonary arterial hypertension
TW202042818A (zh) 2019-01-25 2020-12-01 瑞士商艾克泰聯製藥有限公司 用於治療慢性血栓性肺高血壓之醫藥組成物
IL293271A (en) * 2019-11-29 2022-07-01 Actelion Pharmaceuticals Ltd Methods for treating pulmonary artery hypertension
WO2022180194A1 (en) * 2021-02-26 2022-09-01 Actelion Pharmaceuticals Ltd Methods for treating pulmonary hypertension in patients with left ventricular assist device implantation
WO2026089673A1 (en) * 2024-10-24 2026-04-30 Humanis Sağlik A.Ş. Compositions for pulmonary arterial hypertension

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1693372A1 (en) 2000-12-18 2006-08-23 Actelion Pharmaceuticals Ltd. Novel Sulfamides and their use as endothelin receptor antagonists
ES2393117T3 (es) 2005-09-12 2012-12-18 Actelion Pharmaceuticals Ltd. Composición farmacéutica estable que comprende una pirimidina-sulfamida
AR062501A1 (es) 2006-08-29 2008-11-12 Actelion Pharmaceuticals Ltd Composiciones terapeuticas
MX2010001837A (es) 2007-08-17 2010-03-10 Actelion Pharmaceuticals Ltd Derivados de 4-pirimidinasulfamida.
MX350011B (es) 2008-08-13 2017-08-22 Actelion Pharmaceuticals Ltd Composiciones terapeuticas que contienen macitentan.
IL266518B2 (en) 2016-11-10 2026-05-01 Arena Pharm Inc Methods for treating pulmonary hypertension with combinations of relinfag and other substances
WO2018153925A1 (en) * 2017-02-22 2018-08-30 Amneal Pharmaceuticals Company Gmbh Stable pharmaceutical compositions comprising macitentan
UA126122C2 (uk) 2017-02-27 2022-08-17 Ідорсія Фармасьютікалз Лтд Комбінації похідної 4-піримідинсульфаміду з активними інгредієнтами для лікування захворювань, пов'язаних з ендотеліном
EP3897646B1 (en) 2018-12-21 2024-05-22 Actelion Pharmaceuticals Ltd Macitentan for the treatment of pulmonary arterial hypertension
TW202042818A (zh) 2019-01-25 2020-12-01 瑞士商艾克泰聯製藥有限公司 用於治療慢性血栓性肺高血壓之醫藥組成物
TW202103703A (zh) 2019-04-05 2021-02-01 瑞士商艾克泰聯製藥有限公司 用於治療門脈肺高血壓之方法
JOP20220126A1 (ar) 2019-11-26 2023-01-30 Actelion Pharmaceuticals Ltd تركيبة صيدلانية لعلاج أمراض الأوعية الدموية الرئوية و/أو خلل وظيفي في القلب لمرضى فونتان المُخفّف

Also Published As

Publication number Publication date
US20230020241A1 (en) 2023-01-19
HUE067126T2 (hu) 2024-10-28
LT3897646T (lt) 2024-07-10
JP7871054B2 (ja) 2026-06-08
EP3897646A1 (en) 2021-10-27
JP2022512493A (ja) 2022-02-04
SG11202105098VA (en) 2021-06-29
BR112021011999A2 (pt) 2021-09-08
DK3897646T3 (da) 2024-07-01
EP3897646B1 (en) 2024-05-22
MX2021007455A (es) 2021-08-05
JOP20210153B1 (ar) 2024-12-22
RS65689B1 (sr) 2024-07-31
US20210196715A1 (en) 2021-07-01
HRP20240875T1 (hr) 2024-10-11
MA54522A (fr) 2022-03-23
TW202034923A (zh) 2020-10-01
AU2019410727B2 (en) 2025-05-08
SI3897646T1 (sl) 2024-08-30
ES2983314T3 (es) 2024-10-22
TWI841649B (zh) 2024-05-11
PT3897646T (pt) 2024-07-08
KR20210109558A (ko) 2021-09-06
AU2019410727A1 (en) 2021-08-12
IL284136A (en) 2021-08-31
SMT202400274T1 (it) 2024-09-16
PH12021551371A1 (en) 2021-11-29
ZA202105111B (en) 2023-03-29
US20220096476A1 (en) 2022-03-31
JOP20210153A1 (ar) 2023-01-30
MA54522B1 (fr) 2024-07-31
US11234980B2 (en) 2022-02-01
WO2020128017A1 (en) 2020-06-25
CA3123990A1 (en) 2020-06-25
FI3897646T3 (fi) 2024-06-26
CL2021001636A1 (es) 2022-02-18
CN113194953A (zh) 2021-07-30
CO2021007186A2 (es) 2021-06-10
US11464777B2 (en) 2022-10-11
JP2024105450A (ja) 2024-08-06

Similar Documents

Publication Publication Date Title
LT3897646T (lt) Macitentanas plaučių arterinei hipertenzijai gydyti
IL279260A (en) KDM1A inhibitors for the treatment of diseases
IL275496A (en) Glycolate oxidase inhibitors to treat the disease
LT3496739T (lt) Kompozicijos ir būdai, skirti plaučių hipertenzijai gydyti
GB201500314D0 (en) Pharmaceutical formulations for the treatment of pulmonary arterial hypertension
WO2015027206A8 (en) Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof
EP3810091B1 (en) COMPOSITIONS FOR THE TREATMENT OF PULMONARY HYPERTENSION
IL282311A (en) Use of reboxetine to treat narcolepsy
IL286000A (en) Asketamine for the treatment of depression
PT3573620T (pt) Composições para o tratamento da hipertensão
IL283948A (en) Methods for treating depression
IL281720B2 (en) HMGB1 protein derivatives for biofilm removal
EP3532063C0 (en) POLYTHERAPY FOR THE TREATMENT OF PULMONARY HYPERTENSION
PL3877402T3 (pl) Leczenie skojarzone nadciśnienia tętniczego
PL3484475T3 (pl) 1-Metylonikotynamid do leczenia choroby układu krążenia
HUE058867T2 (hu) Javított vegyület szívelégtelenség kezelésére
ZA202006591B (en) Compositions for the treatment of hypertension
IL280243A (en) Compounds similar to 17beta-heterocyclyl-digitalis for the treatment of heart failure
GB201808575D0 (en) Methods for the treatment of psoriatic arthrits
IL288237A (en) Combination therapy
IL327077A (en) Varsedanib combinations for the treatment of glioma
IT201900020808A1 (it) Composizione per la riduzione del rischio cardiovascolare
IT201900019391A1 (it) Composizione per la riduzione del rischio cardiovascolare
PL3829611T3 (pl) Preparat nutraceutyczny do kontroli nadciśnienia tętniczego
IL288949A (en) Lemborexant for treating sleep issues